Platinum Compounds: A Hope for Future Cancer Chemotherapy

被引：199

作者：

Ali, Imran ^{[1
]}

Wani, Waseem A. ^{[1
]}

Saleem, Kishwar ^{[1
]}

Haque, Ashanul ^{[1
]}

机构：

[1] Jamia Millia Islamia, Dept Chem, New Delhi 110025, India

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2013年 / 13卷 / 02期

关键词：

Cis-platin and its analogues; Comparison of chemotherapies; Mechanism of action; Therapeutic status; Recent developments; Chronology and future perspectives; COPPER TRANSPORTER CTR1; CISPLATIN-MODIFIED DNA; CELL LUNG-CANCER; ANTITUMOR-ACTIVITY; PHASE-II; LOBAPLATIN D-19466; COMBINATION CHEMOTHERAPY; 1ST-LINE TREATMENT; COLORECTAL-CANCER; DRUG CISPLATIN;

D O I：

10.2174/1871520611313020016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The discovery of cis-platin and its second and third generation analogues created a hope in cancer chemotherapy. Cis-platin and its second generation analogue carboplatin have been used for the treatment of some cancers from a long time. The third generation analogues have superior anti-cancer profiles for curing a few cancers. Unfortunately, certain side effects such as renal impairment, neurotoxicity and ototoxicity etc. are associated with these drugs. But, combination therapy makes these analogues more effective with fewer side effects. In addition, the results of some ongoing clinical trials will make the safety profile clear in near future. The present article describes the current status of cis-platin and its analogues in cancer chemotherapy. In addition, special emphasis has been made on cis-platin discovery, development of second (carboplatin, oxaliplatin, nedaplatin) and third (lobaplatin, heptalatin) generation analogues, comparison of their chemotherapies, mechanism of action, therapeutic status, recent developments and chronology. Moreover, attempts have been made to describe the future perspectives of these drugs in the cancer treatment.

引用

页码：296 / 306

页数：11

共 99 条

[21] New trends for metal complexes with anticancer activity [J].

Bruijnincx, Pieter C. A. ;

Sadler, Peter J. .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2008, 12 (02) :197-206

[22]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[23] Drug transporters of platinum-based anticancer agents and their clinical significance [J].

Burger, Herman ;

Loos, Walter J. ;

Eechoute, Karel ;

Verweij, Jaap ;

Mathijssen, Ron H. J. ;

Wiemer, Erik A. C. .

DRUG RESISTANCE UPDATES, 2011, 14 (01) :22-34

[24] KINETICS OF THE DISPLACEMENT OF CYCLOBUTANE-1,1-DICARBOXYLATE FROM DIAMMINE(CYCLOBUTANE-1,1-DICARBOXYLATO)PLATINUM(II) IN AQUEOUS-SOLUTION [J].

CANOVESE, L ;

CATTALINI, L ;

CHESSA, G ;

TOBE, ML .

JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 1988, (08) :2135-2140

[25] Determination by electrospray mass spectrometry of the outersphere association constants of DNA/platinum complexes using 20-mer oligonucleotides and ([Pt(NH3)4]2+, 2Cl-) or ([Pt(py)4]2+, 2Cl-) [J].

Carte, N ;

Legendre, F ;

Leize, E ;

Potier, N ;

Reeder, F ;

Chottard, JC ;

Van Dorsselaer, A .

ANALYTICAL BIOCHEMISTRY, 2000, 284 (01) :77-86

[26] Oxaliplatin-related side effects: Characteristics and management [J].

Cassidy, J ;

Misset, JL .

SEMINARS IN ONCOLOGY, 2002, 29 (05) :11-20

[27] Cisplatin: From DNA damage to cancer chemotherapy [J].

Cohen, SM ;

Lippard, SJ .

PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 67, 2001, 67 :93-130

[28] A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer [J].

Degardin, M ;

Armand, JP ;

Chevallier, B ;

Cappelaere, P ;

Lentz, MA ;

David, M ;

Roche, H .

INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) :253-255

[29]

Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351

[30] RING-OPENING REACTIONS OF THE ANTICANCER DRUG CARBOPLATIN - NMR CHARACTERIZATION OF CIS-[PT(NH3)2(CBDCA-O)(5'-GMP-N7)] IN SOLUTION [J].

FREY, U ;

RANFORD, JD ;

SADLER, PJ .

INORGANIC CHEMISTRY, 1993, 32 (08) :1333-1340

← 1 2 3 4 5 6 7 8 9 10 →